Literature DB >> 16985925

AUA Guidelines and Their Impact on the Management of BPH: An Update.

Steven A Kaplan.   

Abstract

In 1994, the Benign Prostatic Hyperplasia (BPH) Guidelines Panel published recommendations for the diagnosis and treatment of BPH. However, numerous clinical studies occurring after 1994 led to the development of new medical and surgical therapies. Therefore, the American Urological Association published a more relevant set of guidelines in 2003 detailing this new information. Reviewing BPH literature from before and after 1994, along with unpublished data, led to the publication of new guidelines that reported minimally modified diagnosis methods as well as the updated treatment options for patients with modest to severe and bothersome lower urinary tract symptoms associated with BPH.

Entities:  

Year:  2004        PMID: 16985925      PMCID: PMC1472912     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  25 in total

Review 1.  Transurethral resection of the prostate: the new old standard.

Authors:  Joe O Littlejohn; Mohamed A Ghafar; Young M Kang; Steven A Kaplan
Journal:  Curr Opin Urol       Date:  2002-01       Impact factor: 2.309

Review 2.  Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.

Authors:  C G Roehrborn
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

3.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

Authors:  M J Barry; A T Cockett; H L Holtgrewe; J D McConnell; S A Sihelnik; H N Winfield
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

Review 4.  Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia.

Authors:  S A Kaplan; N M Kaplan
Journal:  Urology       Date:  1996-10       Impact factor: 2.649

5.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

Authors:  C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

6.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

Review 7.  Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.

Authors:  Karl-Erik Andersson
Journal:  World J Urol       Date:  2002-04       Impact factor: 4.226

8.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

Authors:  C G Roehrborn; P Boyle; D Bergner; T Gray; M Gittelman; T Shown; A Melman; R B Bracken; R deVere White; A Taylor; D Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

9.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Authors:  H Lepor; W O Williford; M J Barry; M K Brawer; C M Dixon; G Gormley; C Haakenson; M Machi; P Narayan; R J Padley
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

10.  Symptom status and quality of life following prostatectomy.

Authors:  F J Fowler; J E Wennberg; R P Timothy; M J Barry; A G Mulley; D Hanley
Journal:  JAMA       Date:  1988-05-27       Impact factor: 56.272

View more
  10 in total

1.  Prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-w high-intensity diode laser.

Authors:  Po-Hui Chiang; Chien-Hsu Chen
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

2.  [Diode laser. Ex vivo studies on vaporization and coagulation characteristics].

Authors:  M Seitz; A Ackermann; C Gratzke; B Schlenker; R Ruszat; A Bachmann; C Stief; O Reich; R Sroka
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

3.  Ex vivo and in vivo investigations of the novel 1,470 nm diode laser for potential treatment of benign prostatic enlargement.

Authors:  Michael Seitz; Robin Ruszat; Thomas Bayer; Derya Tilki; Alexander Bachmann; Christian Stief; Ronald Sroka; Oliver Reich
Journal:  Lasers Med Sci       Date:  2008-08-07       Impact factor: 3.161

4.  The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations.

Authors:  Andrew C Peterson; Abigail R Smith; Matthew O Fraser; Claire C Yang; John O L DeLancey; Brenda W Gillespie; John L Gore; Pooja Talaty; Victor P Andreev; Karl J Kreder; Margaret G Mueller; H Henry Lai; Bradley A Erickson; Ziya Kirkali
Journal:  Urology       Date:  2019-04-21       Impact factor: 2.649

5.  High-power diode laser at 980 nm for the treatment of benign prostatic hyperplasia: ex vivo investigations on porcine kidneys and human cadaver prostates.

Authors:  Michael Seitz; Oliver Reich; Christian Gratzke; Boris Schlenker; Alexander Karl; Markus Bader; Wael Khoder; Florian Fischer; Christian Stief; Ronald Sroka
Journal:  Lasers Med Sci       Date:  2008-02-13       Impact factor: 3.161

Review 6.  Dutasteride: a review of its use in the management of prostate disorders.

Authors:  Susan J Keam; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.

Authors:  Andrew Thomson
Journal:  Core Evid       Date:  2005-06-30

8.  Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study.

Authors:  M Hammad Mithani; Salman El Khalid; Shariq Anis Khan; Imran Sharif; Adnan Siddiq Awan; Shoaib Mithani; Irfan Majeed
Journal:  Investig Clin Urol       Date:  2018-10-18

9.  Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH).

Authors:  Miriam Saponaro; Isabella Giacomini; Giulia Morandin; Veronica Cocetta; Eugenio Ragazzi; Genny Orso; Ilaria Carnevali; Massimiliano Berretta; Mariangela Mancini; Francesco Pagano; Monica Montopoli
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

10.  High regional variation in prostate surgery for benign prostatic hyperplasia in Switzerland.

Authors:  Maria M Wertli; Brigitta Zumbrunn; Pascal Weber; Alan G Haynes; Radoslaw Panczak; Arnaud Chiolero; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.